Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback